DrugPatentWatch Database Preview
LYRICA CR Drug Profile
Which patents cover Lyrica Cr, and what generic alternatives are available?
Lyrica Cr is a drug marketed by Pf Prism Cv and is included in one NDA. There are five patents protecting this drug and four Paragraph IV challenges.
This drug has one hundred and four patent family members in forty-five countries.
The generic ingredient in LYRICA CR is pregabalin. There are forty-one drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the pregabalin profile page.
Summary for LYRICA CR
| International Patents: | 104 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Clinical Trials: | 81 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for LYRICA CR |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LYRICA CR |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for LYRICA CR |
| DailyMed Link: | LYRICA CR at DailyMed |
Medical Subject Heading (MeSH) Categories for LYRICA CR
US Patents and Regulatory Information for LYRICA CR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | LYRICA CR | pregabalin | TABLET, EXTENDED RELEASE;ORAL | 209501-001 | Oct 11, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Pf Prism Cv | LYRICA CR | pregabalin | TABLET, EXTENDED RELEASE;ORAL | 209501-003 | Oct 11, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Pf Prism Cv | LYRICA CR | pregabalin | TABLET, EXTENDED RELEASE;ORAL | 209501-001 | Oct 11, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for LYRICA CR
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 82.5 mg and 165 mg | ➤ Subscribe | ➤ Sign Up |
| ➤ Subscribe | Extended-release Tablets | 82.5 mg and 165 mg | ➤ Subscribe | ➤ Sign Up |
| ➤ Subscribe | Extended-release Tablets | 330 mg | ➤ Subscribe | ➤ Sign Up |
| ➤ Subscribe | Extended-release Tablets | 330 mg | ➤ Subscribe | ➤ Sign Up |
International Patents for LYRICA CR
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Serbia | 20080181 | ➤ Sign Up |
| New Zealand | 567414 | ➤ Sign Up |
| Japan | 2009514847 | ➤ Sign Up |
| Country | Patent Number | Estimated Expiration |
Supplementary Protection Certificates for LYRICA CR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0934061 | PA2004017,C0934061 | Lithuania | ➤ Sign Up | PRODUCT NAME: PREGABALINUM ((S)-3-(AMINOMETIL)-5-METILHEKSANO RUGSTIS); REGISTRATION NO/DATE: EU/1/04/279/001-025 20040725 |
| 0641330 | CA 2004 00036 | Denmark | ➤ Sign Up | |
| 0641330 | C00641330/01 | Switzerland | ➤ Sign Up | FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
